LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

Hongbin Zhang; Ke Xu; Qin Xiang; Lijuan Zhao; Benxu Tan; Ping Ju; Xiufu Lan; Yi Liu; Jian Zhang; Zheng Fu; Chao Li; Jinzhi Wang; Jixiang Song; Yun Xiao; Zhaobo Cheng; Yan Wang; Shu Zhang; Tingxiu Xiang

doi:10.1016/j.gendis.2020.07.007

您当前的位置：

首页 >

文章列表页 >

LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

更新时间：2022-06-24

- LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma
- Genes & Diseases Vol. 9, Issue 1, (2022)
- 作者机构：
  
  1. Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science,Shandong,Jinan,PR China,250117
  2. Department of Oncology, People's Hospital of Juxian County,Shandong,Rizhao,PR China,276599
  3. Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University,Chongqing,PR China,400016
  4. Department of Oncology, The First Affiliated Hospital of Chengdu Medical College,Sichuan,Chengdu,PR China,610599
  5. Department of Oncology, Yongchuan Hospital of Chongqing Medical University,Chongqing,PR China,402177
  6. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University,Chongqing,PR China,400016
  7. College of Science and Mathematics, West Chester University of Pennsylvania, West Chester,PA,USA,19383
  8. Department of Orthopedics, Daping Hospital, Army Medical University,Chongqing,PR China,400042
  9. Engineering Department, Women & Children's Health Care Hospital of Linyi,Shandong,Linyi,PR China,276016
  10. Department of Oncology, Central Hospital Affiliated to Shandong First Medical University,Shandong,Jinan,PR China,250013
  11. Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science,Shandong,Jinan,PR China,250013
  12. Medical Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science,Shandong,Jinan,PR China,250013
  13. Department of Oncology, Chongqing Traditional Chinese Medicine Hospital,Chongqing,PR China,400042
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.07.007
  CLC：
- Published：2022，
  
  Published Online：1 January 2022，
扫描看全文
Hongbin Zhang, Ke Xu, Qin Xiang, et al. LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma. [J]. Genes & Diseases 9(1).(2022)
DOI：

Hongbin Zhang, Ke Xu, Qin Xiang, et al. LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma. [J]. Genes & Diseases 9(1).(2022) DOI： 10.1016/j.gendis.2020.07.007.

摘要

Abstract

This study aimed to investigate the relationships between LPCAT1 expression and clinicopathologic parameters of hepatocellular carcinoma (HCC)

further

to explore the effect of LPCAT1 on overall survival (OS) in patients with HCC

and its possible mechanism. Bioinformatics analysis using high throughput RNA-sequencing data from TCGA was utilized to explore the differential expression of LPCAT1 between normal and tumor tissues

and the associations between LPCAT1 expression and clinicopathological parameters. Survival analyses and subgroup survival analyses were utilized to elucidate the effect of LPCAT1 on OS in patients with HCC. Univariate analysis and multivariate analysis were used to investigate the prognostic factors. Potential LPCAT1 related tumor genes were identified by the methodology of differentially expressed genes (DEGs) screening. GO term enrichment analysis

KEGG pathway analysis and the PPI network were used to explore the potential mechanism. LPCAT1 was significantly overexpressed in HCC tumor tissues compared with normal tissues. The LPCAT1 expression was related to tumor grade

ECOG score

AFP and TNM stage

with

values of 0.000

0.000

0.007 and 0.000

respectively. Multivariate analysis demonstrated that LPCAT1 expression was independently associated with OS

with an HR of 1.04 (CI: 1.01–1.06

= 0.003). The KEGG pathway enrichment analyses showed that overlapped DEGs mainly participate in the cell cycle. Finally

we identified a hub gene

CDK1

which has been reported to act on the cell cycle

consistent with the result of KEGG enrichment analysis. Collectively

these data confirmed LPCAT1 was upregulated in HCC

and was an independent predictor of the prognosis.

关键词

Keywords

CDK1HCCLPCAT1Overall survivalPrognostic marker

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application and progress of the detection technologies in hepatocellular carcinoma

Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients

Comprehensive biological function analysis of lncRNAs in hepatocellular carcinoma

Hepatic SIRT6 deficit promotes liver tumorigenesis in the mice models

Related Author

Jian Du

Lijian Chen

Tao Xu

Zhen Wang

Qi Fang

Fang Liu

Ran An

Yuan-song Sun

Related Institution

Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University

School of Basic Medical Sciences, Anhui Medical University

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy

Institute for Liver Diseases of Anhui Medical University, Anhui Medical University

Department of Emergency Surgery, The Second Hospital of Anhui Medical University

⁰